1. J. W. Hadden, Immunotherapy of human immunodeficiency virus (HIV), Trends in Pharmacol. 12:107 (1991).
2. C. DeSimone, S. Antonaci, M. Chirigos, S. Delia, S. Difabio, R.A. Good, J.W. Hadden, E. Jirillo, R. Lockey, F. Milazzo, G. Scalise, M. Tinelli, Report of the symposium on the use of intravenous gamma globulin (IVIG) in adults infected with HIV, J. Clin. Lab. Analysis 4:313 (1990).
3. E. M. Hersh, G. Brewton, D. Adams, J. Galpin, J. Bartlett, P. Gill, R. Gorter, M. Gottlieb, J. Jonikas, S. Landesman, A. Levine, A. Marcel, E.A. Peterson, M. Whiteside, J. Zahradnik, C. Negron, F. Boutitie, J. Caraux, J.M. Dupuy and L.R. Salmi, Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double blind, placebo-controlled, multicenter study, JAMA 265(12):1538 (1991).
4. C. Pederson, E. Sandstrom, C.S. Peterson, G. Norkrans, J. Gersteft, A. Karlsonn, K.C. Christiansen, C. Hadansson, P. Pehrson, J.O. Nielson, H.J. Jurgensen and the Scandinavian Isoprinosine Study Group, The efficacy of inosine pranobex in preventing the acquired immunodeficiency virus infection, New Eng. J. Med. 322:1757 (1990).
5. S. E. Thompson et al., Effects of thymopentin on disease progression and surrogate markers in HIV infection, VI Int. Conf. AIDS ,San Francisco 3:207 (1990).